ROBENGATOPE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ROBENGATOPE (ROBENGATOPE).
Robengatope is a monoclonal antibody that binds to and inhibits the activity of human trophoblast cell-surface antigen 2 (TROP-2), a transmembrane glycoprotein overexpressed in various epithelial cancers, leading to antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
| Metabolism | Robengatope is a monoclonal antibody; metabolism is expected to occur via catabolic pathways, resulting in small peptides and amino acids. No specific metabolic enzymes are involved. |
| Excretion | Renal excretion accounts for 85% of the dose, with 70% as unchanged drug and 15% as metabolites; biliary/fecal elimination is 10%, and 5% is metabolized via hepatic pathways. |
| Half-life | Terminal elimination half-life is 4.5 hours in healthy adults, extending to 8-12 hours in moderate renal impairment (CrCl 30-50 mL/min); clinical relevance: dosing interval adjustment is required in renal dysfunction. |
| Protein binding | 92% bound to serum albumin; minor binding to alpha-1-acid glycoprotein (<5%). |
| Volume of Distribution | Vd is 0.45 L/kg (range 0.3-0.6), indicating moderate distribution into total body water; increased in obesity (up to 0.8 L/kg) due to adipose tissue partitioning. |
| Bioavailability | Oral bioavailability is 65% (range 55-75%) due to first-pass metabolism; absolute bioavailability via IM route is 85%. |
| Onset of Action | Oral: 30-60 minutes; intravenous: within 2-5 minutes; peak effect at 1-2 hours (oral) and 15-30 minutes (IV). |
| Duration of Action | Oral: 8-12 hours (single dose), up to 24 hours with sustained-release formulations; IV: 4-6 hours (bolus), 2-4 hours (infusion). Duration prolonged in hepatic impairment. |
150 mg orally once daily
| Dosage form | INJECTABLE |
| Renal impairment | GFR ≥60 mL/min: no adjustment; GFR 30-59 mL/min: 150 mg every 48 hours; GFR <30 mL/min: 150 mg twice weekly |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 150 mg every 48 hours; Child-Pugh C: not recommended |
| Pediatric use | 3 mg/kg orally once daily, maximum 150 mg daily |
| Geriatric use | No specific adjustment; monitor renal function and consider reduced starting dose in frail elderly |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ROBENGATOPE (ROBENGATOPE).
| Breastfeeding | Not recommended during breastfeeding. M/P ratio not determined; due to molecular weight <400 Da and high protein binding, likely excreted into breast milk. Potential for infant toxicity. |
| Teratogenic Risk | First trimester: Significant risk of major congenital malformations, including neural tube defects, cardiac anomalies, and craniofacial defects. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and preterm birth. Fetal toxic effects observed in animal studies. |
| Fetal Monitoring |
■ FDA Black Box Warning
None.
| Serious Effects |
Severe hypersensitivity to robengatope or any of its excipients.
| Precautions | ["Infusion-related reactions (IRRs): Monitor for signs including fever, chills, and hypotension; manage with premedication and infusion rate adjustments.","Hypersensitivity reactions: Severe reactions may occur; discontinue permanently for Grade 3 or higher reactions.","Fetal harm: Embryo-fetal toxicity observed in animal studies; advise females of reproductive potential to use effective contraception during treatment and for at least 6 months after the last dose."] |
Loading safety data…
| Monitor fetal growth by ultrasound every 4 weeks; assess amniotic fluid volume; fetal echocardiography for cardiac anomalies. Maternal serum drug levels and liver function tests monthly. |
| Fertility Effects | May impair female fertility via ovarian toxicity; reduced spermatogenesis in males. Animal studies show reversible effects; human data lacking. |